Obalon Therapeutics, Inc.
OBLN · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $35 | $1,242 | $1,113 | $7,941 |
| % Growth | -97.2% | 11.6% | -86% | – |
| Cost of Goods Sold | $17 | $643 | $432 | $2,947 |
| Gross Profit | $18 | $599 | $681 | $4,995 |
| % Margin | 52.1% | 48.2% | 61.2% | 62.9% |
| R&D Expenses | $40 | $476 | $364 | $1,534 |
| G&A Expenses | $0 | $1,591 | $1,627 | $5,697 |
| SG&A Expenses | $844 | $2,174 | $2,156 | $4,630 |
| Sales & Mktg Exp. | $0 | $583 | $529 | $2,990 |
| Other Operating Expenses | $7,692 | $68 | $0 | $2 |
| Operating Expenses | $8,576 | $2,718 | $2,520 | $6,166 |
| Operating Income | -$8,558 | -$2,119 | -$1,839 | $2,527 |
| % Margin | -24,714% | -170.6% | -165.2% | 31.8% |
| Other Income/Exp. Net | -$38 | -$503 | $3,320 | -$4,122 |
| Pre-Tax Income | -$8,595 | -$2,622 | $1,481 | -$1,595 |
| Tax Expense | $0 | $8 | $7 | $38 |
| Net Income | -$8,595 | -$2,630 | $1,474 | -$1,634 |
| % Margin | -24,822.5% | -211.8% | 132.4% | -20.6% |
| EPS | 0 | -2.25 | 18.98 | -13.22 |
| % Growth | 100% | -111.9% | 243.6% | – |
| EPS Diluted | 0 | -2.25 | 18.98 | -13.22 |
| Weighted Avg Shares Out | 0 | 1,169 | 777 | 516 |
| Weighted Avg Shares Out Dil | 0 | 1,169 | 777 | 516 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $26 | $18 | $40 | $0 |
| Depreciation & Amortization | $3 | $0 | $0 | -$245 |
| EBITDA | -$8,567 | -$2,119 | -$1,839 | -$1,841 |
| % Margin | -24,740.5% | -170.6% | -165.2% | -23.2% |